GLP1R and fatty liver disease: Encouraged by several experimental and open-label uncontrolled clinical studies [2], the current placebo-controlled randomised trial assessed the effects of the GLP-1 receptor agonist liraglutide and the DPP-4 inhibitor sitagliptin on spectroscopy-measured hepatic steatosis in patients with type 2 diabetes.